Abstract
We herein report a case of an ectopic breast carcinoma of the right axilla treated with preoperative endocrine therapy. A 65-year-old female presented with an ulcerated mass in the right axilla. The tumor was 1.7 cm in diameter. The clinical and pathological diagnosis based on the findings of a core needle biopsy (ER-positive and PR-positive) was ectopic breast carcinoma of the axilla. The tumor was widely spread in the right axilla. We were concerned that an extensive scar that would result from surgery would restrict the range of motion of the right upper extremity. The estrogen receptor was highly expressed in the tumor, therefore, neoadjuvant endocrine therapy was started. Letrozole, an aromatase inhibitor, was administrated for 6 months before surgery, and the tumor was reduced in size and became easily resectable. The clinicopathological effect was a partial response. The resection of the right axilla and axillary lymph node dissection were performed. The defect of the right axilla was small, and no contracture occurred. Adjuvant endocrine therapy was continued after surgery. To the best of our knowledge, this is the first report of a case of ectopic breast carcinoma of the axilla successfully treated with neoadjuvant endocrine therapy. This case is considered to be a valuable case, and we have added some bibliographic considerations to further increase the value of this report.
This is a preview of subscription content, log in via an institution to check access.
References
Sanguinetti A, Ragusa M, Calzolari F et al (2010) Invasive ductal carcinoma arising in ectopic breast tissue of the axilla. case report and review of the literature. G Chir 31:383–386
Colleoni M, Montagna E (2012) Neoadjuvant therapy for ER-positive breast cancers. Ann Oncol 23(Suppl 10):x243–x248
Fisher B, Bryant J, Wolmark N et al (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672–2685
Guarneri V, Broglio K, Kau SW et al (2006) Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 24:1037–1044
Kuerer HM, N L, Smith TL, Ames FC, Hunt KK, Dhingra K, Theriault RL, Singh G, Binkley SM, Sneige N, Buchholz TA, Ross MI, McNeese MD, Buzdar AU, Hortobagyi GN, Singletary SE (1999) Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17:460–469
Ellis MJ, Coop A, Singh B et al (2001) Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 19:3808–3816
Smith IE, Dowsett M, Ebbs SR et al (2005) Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the immediate preoperative anastrozole, tamoxifen, or combined with tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 23:5108–5116
Gutermuth J, Audring H, Voit C et al (2006) Primary carcinoma of ectopic axillary breast tissue. J Eur Acad Dermatol Venereol 20:217–221
Visconti G, Eltahir Y, Van Ginkel RJ et al (2011) Approach and management of primary ectopic breast carcinoma in the axilla: where are we? a comprehensive historical literature review. J Plast Reconstr Aesthet Surg 64:e1–e11
Wick MR, Ockner DM, Mills SE et al (1998) Homologous carcinomas of the breasts, skin, and salivary glands. a histologic and immunohistochemical comparison of ductal mammary carcinoma, ductal sweat gland carcinoma, and salivary duct carcinoma. Am J Clin Pathol 109:75–84
Routiot T, Marchal C, Verhaeghe JL et al (1998) Breast carcinoma located in ectopic breast tissue: a case report and review of the literature. Oncol Rep 5:413–417
Yerra L, Karnad AB, Votaw ML (1997) Primary breast cancer in aberrant breast tissue in the axilla. South Med J 90:661–662
Abrial C, Mouret-Reynier MA, Cure H et al (2006) Neoadjuvant endocrine therapy in breast cancer. Breast 15:9–19
Semiglazov VF, Semiglazov VV, Dashyan GA et al (2007) Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. Cancer 110:244–254
Mouridsen H, Gershanovich M, Sun Y et al (2001) Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the international letrozole breast cancer group. J Clin Oncol 19:2596–2606
Dowsett M, Cuzick J, Ingle J et al (2010) Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 28:509–518
Seo JH, Kim YH, Kim JS (2009) Meta-analysis of pre-operative aromatase inhibitor versus tamoxifen in postmenopausal woman with hormone receptor-positive breast cancer. Cancer Chemother Pharmacol 63:261–266
Toi M, Saji S, Masuda N et al (2011) Ki67 index changes, pathological response and clinical benefits in primary breast cancer patients treated with 24 weeks of aromatase inhibition. Cancer Sci 102:858–865
Llombart-Cussac A, Guerrero A, Galan A et al (2012) Phase II trial with letrozole to maximum response as primary systemic therapy in postmenopausal patients with ER/PgR[+] operable breast cancer. Clin Transl Oncol 14:125–131
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Taketani, K., Tokunaga, E., Yamashita, N. et al. A case of ectopic breast carcinoma of the right axilla treated with neoadjuvant endocrine therapy. Int Canc Conf J 4, 29–34 (2015). https://doi.org/10.1007/s13691-014-0164-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13691-014-0164-8